Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 7.0 Contact Hours.


PER Pulse™ Recaps highlight key elements of the Community Practice Connections™: 4th Annual Miami Lung Cancer Conference® online activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; Ariad Pharmaceuticals, Inc; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Genentech; Lilly; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; and Takeda Oncology.

For further information concerning Lilly grant funding, visit

Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®

Release Date: June 30, 2017
Expiration Date: June 30, 2018
Media: Internet - based


Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 4th Annual Miami Lung Cancer Conference®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of lung cancer, including immunotherapies in development, molecular subsets and targeted agents, the emergence of liquid biopsies, and the management of patients without actionable mutations.

Our program chair, Heather A. Wakelee, MD, and our expert faculty, Christina Baik, MD, MPH; Julie Brahmer, MD; Justin F. Gainor, MD; Sarah B. Goldberg, MD, MPH; Sukhmani K. Padda, MD; Rathi Pillai, MD; Karen L. Reckamp, MD; and Gregory Riely, MD, PhD, emphasize the cutting-edge clinical research that will shape the therapy of lung cancer in the near future. Our community oncology representatives, Debra S. Brandt, MD, and Luis E. Raez, MD, FACP, FCCP, complement the academic perspective provided by our faculty.

Each brief, 10-minute presentation will be followed by an extensive question-and-answer segment led by Dr. Wakelee or Dr. Brahmer. This extended discussion format will allow ample time for examining the nuances and challenges faced by clinicians in everyday practice and include a discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; Ariad Pharmaceuticals, Inc; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Bristol-Myers Squibb; Genentech; Lilly; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; and Takeda Oncology.

For further information concerning Lilly grant funding, visit

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Discuss evidence-based recommendations regarding tumor tissue testing and its role in therapeutic selection for patients with non–small cell lung caner (NSCLC)
  2. Assess clinical decision making along multiple lines of care concerning the use of chemotherapeutic, targeted, and immuno-oncology strategies in the setting of NSCLC
  3. Discuss evolving data sets on immuno-oncology strategies and their use in lung cancers
  4. Describe the role of cytotoxic and antiangiogenic approaches in the management of advanced NSCLC
  5. Explain optimized strategies to target oncogenic drivers in frontline settings and beyond disease progression
  6. Describe advances and future directions for care in the management of squamous NSCLC, as well as treatment considerations for special populations of patients with lung cancer
  7. Integrate personalized approaches to manage challenging cases and real-world clinical scenarios in advanced lung cancer settings

Faculty, Staff, and Planners' Disclosures


Christina Baik, MD, MPH
Thoracic, Head and Neck Medical Oncology Seattle Cancer Care Alliance Fred Hutchinson Cancer Research Center University of Washington
Seattle, WA

Disclosure: Grant/Research Support: Celgene, Novartis, Clovis Oncology, Genentech, Loxo Oncology, Incyte, Millennium; Consultant: Clovis Oncology, Novartis

Julie Brahmer, MD
Interim Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Disclosure: Grant/Research Support: Bristol-Myers Squibb, MedImmune/AstraZeneca, Merck; Consultant: Bristol-Myers Squibb (uncompensated), Celgene, Lilly, Merck Sharp & Dohme Corp

Justin F. Gainor, MD
Instructor, Medicine, Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
Boston, MA

Disclosure: Consultant: Novartis, Bristol-Myers Squibb, Genentech, Theravance Biopharma, Loxo Oncology; Honoraria: Merck, Incyte

Sarah B. Goldberg, MD, MPH
Assistant Professor of Internal Medicine
Medical Oncology
Yale Cancer Center
New Haven, CT

Disclosure: Grant/Research Support: AstraZeneca

Sukhmani K. Padda, MD
Instructor of Medicine
Stanford University Medical Center
Stanford, CA

Disclosure: Consultant: Sukhmani K. Padda, MD

Rathi Pillai, MD
Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosure: Consultant: AstraZeneca

Luis E. Raez, MD, FACP, FCCP
Chief Hematology/Oncology & Medical Director
Memorial Cancer Institute
Memorial Health Care System
Clinical Associate Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Miami, FL

Disclosure: Grant/Research Support: Roche, Bristol-Myers Squibb, Pfizer, Novartis, Merck, AstraZeneca

Karen L. Reckamp, MD
Associate Professor
City of Hope Comprehensive Cancer Center
Duarte, CA

Disclosure: Grant/Research Support: Ariad, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis Oncology, Pfizer, Xcovery, Genentech, Adaptimmune, AbbVie; Consultant: Amgen, Astellas Pharma, Ariad

Gregory Riely, MD, PhD
Vice Chair, Clinical Trials Office
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Roche, Novartis, Infinity, Millennium, Ariad, GlaxoSmithKline, Pfizer; Consultant: Novartis, Genentech

Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Disclosure: Grant/Research Support: Clovis Oncology, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, Bristol-Myers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly; Consultant: Peregrine Pharmaceuticals, Pfizer, ACEA Biosciences, Helsinn, Genentech (uncompensated)

Aiwu Ruth He, MD, PhD
Associate Professor of Medicine
Division of Hematology/Oncology
Georgetown University School of Medicine
Washington, DC

Disclosure: Grant/Research Support: Merck Sharp & Dohme, EMD Serono; Consultant: Bayer, Bristol-Myers Squibb; Advisory Board: Bayer, Bristol-Myers Squibb, Merck Sharp & Dohme

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recap

1 of 3
PER Pulse™ Recap

Updates on First-Line Therapy in EGFR Mutation-Positive NSCLC

The 4th Annual Miami Lung Cancer Conference™, which was held on April 8, 2017, featured internationally recognized experts in thoracic malignancies. These experts, along with representatives from community practice, discussed key advances in the treatment of patients with lung cancer. This first of 3 PER Pulse™ Recaps from the Miami Lung Cancer Conference focuses on recent data comparing tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR).

Currently, erlotinib, gefitinib, and afatinib are approved as first-line therapy for patients with non–small cell lung cancer (NSCLC) and mutations in the EGFR gene. Until the randomized phase II LUX-Lung 7 trial, data on direct comparisons between these agents were lacking (Table). Subsequently, the phase III ARCHER 1050 compared the second-generation EGFR TKI dacomitinib to gefitinib; this trial excluded patients with brain metastases; however. Finally, the phase III FLAURA trial compared osimertinib, which also targets the T790M resistance mutation, to either erlotinib or gefitinib.


EGFR, epidermal growth factor receptor; ORR, overall response rate; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.

For additional commentary about this topic and others, visit to access additional resources from the 4th Annual Miami Lung Cancer Conference™, including downloadable slides from the meeting.

Become a Member

Forgot Password?
Calendar of Events
Filter By